CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-3800015, Gujarat.
Phone: +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

October 28, 2026

To The Manager, Listing Department **National Stock Exchange of India Limited** Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960

Sub.: Press Release- For the Second quarter and half year ended on September 30, 2026

Dear Sir/Ma'am,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026 as published in the below Newspapers on October 28, 2026.

The Details of the publications are as follows:

Sr. No	Newspaper	Language	Editions
1	Financial Express	English	All
2	Financial Express	Gujarati	Ahmedabad

Further, in terms of Regulation 46 of the Listing Regulations, the aforesaid audited financial results are also uploaded on the website of the Company (www.concordbiotech.com)

Kindly take the above on records.

Thanking you,

For Concord Biotech Limited

Paritosh Trivedi
Digitally signed by Paritosh Trivedi
Date: 2026.10.28 14:30:02 +05'30'

Paritosh Trivedi
Company Secretary and Compliance Officer
ACS 63623

Encl: as above

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026 Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items#)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)]	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.
b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com
c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com
d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

Place: Mumbai
Date: 27-10-2026

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :- (₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors
Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

CONCORD BIOTECH
Biotech for Mankind...

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

Ahmedabad

यूनियन बैंक Union Bank of India

જોધપુર ટેકરા શાખા, સિગ્મા આઈકોન-II, ૧૩૨ ફૂટ રિંગ રોડ, મેડિલિંક હોસ્પિટલની સામે, ટામેટો હોટેલની નજીક, સેટેલાઇટ, અમદાવાદ – ૩૮૦૦૧૫.
ઈ-મેઇલ: ubin0542237@unionbankofindia.bank

[Rule-8(1)] કબજાની નોટીસ (સ્થાવર મિલકત માટે)

આથી નીચે સહી કરનાર **યુનિયન બેંક ઓફ ઇન્ડિયા, જોધપુર ટેકરા શાખા, સિગ્મા આઈકોન-II, ૧૩૨ ફૂટ રિંગ રોડ, મેડિલિંક હોસ્પિટલની સામે, ટામેટો હોટેલની નજીક, સેટેલાઇટ, અમદાવાદ - ૩૮૦૦૧૫.** ના અધિકૃત અધિકારીએ સિક્યોરિટાઇઝેશન એન્ડ રીકન્સ્ટ્રકશન ઑફ ફાયનાન્સિયલ એસેટ્સ એન્ડ એન્ફોર્સમેન્ટ ઑફ સિક્યોરિટી ઇન્ટરેસ્ટ એક્ટ, ૨૦૦૨ (૨૦૦૨ નો એક્ટ નં. ૫૪) ના તથા નિયમ ૩ ની સાથે વંચાતી કલમ ૧૩(૧૨) હેઠળ મળેલ સત્તા સાથે સિક્યોરિટી ઇન્ટરેસ્ટ (એન્ફોર્સમેન્ટ) નિયમો, ૨૦૦૨ અંતર્ગત **તા. ૩૦.૦૭.૨૦૨૫** ના રોજ ડિમાન્ડ નોટિસ જારી કરેલ હતી જેમાં કરજદાર **શ્રી પંકજ અજુભાઈ રાઠોડ** ને નોટિસમાં જણાવેલ **રૂ. ૨૭,૫૪,૫૫૦.૪૯/- (રૂપિયા સત્તાવીસ લાખ ચોપન હજાર પાંચસો પચાસ અને પૈસા ઓગણપચાસ માત્ર)** સદર નોટિસ પ્રાપ્ત થયાની તારીખથી ૬૦ દિવસોમાં ચૂકવવા જણાવવામાં આવ્યું હતું.

કરજદાર આ રકમ ચુકવવામાં અસફળ રહેલ છે. આથી કરજદાર અને જાહેર જનતાને જણાવવામાં આવે છે કે **તા. ૨૨.૧૦.૨૦૨૫** ના રોજ ઉપરોકત નિયમનોની સાથે વંચાતા નિયમ ૮ ની સાથે ધારા ૧૩(૪)ના અંતર્ગત અને ઉપરોકત નિયમ અંતર્ગત નીચે હસ્તાક્ષર કરેલ અધિકારીએ પોતાના અધિકારથી નીચે દર્શાવેલ મિલકતનો **કબજો** મેળવેલ છે.

આથી વિશેષપણે અરજદાર/સહ-અરજદાર/જામીનદાર અને સામાન્ય પણે જાહેર જનતાને આ મિલકત અંગે કોઈપણ વ્યવહાર નહીં કરવા ચેતવણી આપવામાં આવે છે અને આ મિલકત અંગેનો કોઈપણ વ્યવહાર **યુનિયન બેંક ઑફ ઇન્ડિયાના રૂ. ૨૭,૫૪,૫૫૦.૪૯/- (રૂપિયા સત્તાવીસ લાખ ચોપન હજાર પાંચસો પચાસ અને પૈસા ઓગણપચાસ માત્ર) તા. ૩૦.૦૬.૨૦૨૬ સુધી** ચડત વ્યાજ અને ખર્ચાની રકમના બોજાને આધિન રહેશે.

કરજદારો/જામીનદારો/ગીરોદારોને અધિનિયમ કલમ ૧૩ ની પેટા કલમ(૮) મુજબ ઉપલબ્ધ સમયમાં સુરક્ષિત અકસ્થામતો પરત લેવા માટે આમંત્રિત કરેલ છે.''

સ્થાવર મિલકતોનું વર્ણન

બધા હક અને હિસ્સા સાથેની બિનખેતીની જમીનનો તમામ ટુકડો અને ભાગ, જે મોજે ચાલોડા, તાલુકો ધોળકા ખાતે આવેલી, સર્વે નં. ૧૪૫૭ની કુલ ૧૪૨૬૫ ચો.મી. પૈકીની પ્લોટ નં. એ/૧૪, ક્ષેત્રફળ ૨૯૫ ચો.મી. એટલે કે ૩૧૨.૭૪ ચો.વાર (ઓસ પ્લોટ), જેના ઉપર ૮૪ ચો.મી. (સુપર બિલ્ટ–અપ) બાંધકામ આવેલ છે, તેમજ 'રોઝ એન્ડ કાઉન' તરીકે ઓળખાતી સ્કીમમાં આવેલા સામાન્ય રસ્તાઓ અને સામાન્ય પ્લોટોનો ઉપયોગ કરવાનો અધિકાર સહિતની, અમદાવાદ નોંધણી જિલ્લા અને ધોળકા પેટા–જિલ્લામાં આવેલી, શ્રી પંકજ અજુભાઈ રાઠોડના નામે ધારણ કરેલી સ્થાવર મિલકત. જેની ચતુઃસીમા નીચે મુજબ છેઃ પૂર્વેઃ પ્લોટ નં. એ/૧૩, પશ્ચિમેઃ પ્લોટ નં. એ/૧૫, ઉત્તરેઃ કમ્પાઉન્ડ વોલ, દક્ષિણેઃ આંતરિક રસ્તો.

તારીખ : ૨૨.૧૦.૨૦૨૫, સ્થળ : અમદાવાદ **અધિકૃત અધિકારી યુનિયન બેંક ઑફ ઇન્ડિયા**

AUSTIN ENGINEERING CO. LTD.

CIN : L27259GJ1978PLC003179
Regd.Office : Patla, Tal.Bhesan, Dist. Junagadh 362 030
Phone : 02873 – 252223 website : www.aec.com

NOTICE

Notice is hereby given that, Pursuant to Regulations 29 and 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, with the Stock Exchange that, the Board of Directors Meeting of the Austin Engineering Company Limited Will be held on **Thursday,** the **5 th November, 2026** at registered office of the company at 2.00 p.m. to consider and approve the Unaudited Financial Result for the quarter ended **30 th September,2026.**

Notice is Also Available on the Company's website **www.aec.com** and BSE website.

For Austin Engg. Co. Ltd.
sd/-
R. R. Bambhania
Managing Director

Dated : 26-10-2026

Drishty-26

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026 **Name of the Holder: Bharat Shyam Bhatia**

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

Arcil એસેટ રીકન્સ્ટ્રક્શન કંપની (ઇન્ડિયા) લીમીટેડ.

આર્સિલ ઓફીસ : ધ રૂબી, ૧૦મો માળ, ૨૯ સેનાપતી બાપટ માર્ગ, દાદર (પશ્ચિમ), મુંબઇ–૪૦૦૦૨૮

કબજા નોટીસ

આથી મથૂટ હાઉસિંગ ફાયનાન્સ કંપની લીમીટેડે સિક્યોરીટાઇઝેશન અને રીકન્સ્ટ્રક્શન ઓફ ફાયનાન્સિયલ એસેટ્સ અને એન્ફોર્સમેન્ટ ઓફ સિક્યોરીટી ઇન્ટરેસ્ટ એક્ટ, ૨૦૦૨ (૨૦૦૨નો ૫૪) (જણાવેલ એક્ટ)ની જોગવાઈઓ હેઠળ અને સિક્યોરીટી ઇન્ટરેસ્ટ એક્ટ, ૨૦૦૨ (જણાવેલ નિયમો) ના નિયમ ૩ સાથે વંચાતી કલમ ૧૩(૧૨) હેઠળ પ્રાપ્ત સત્તાનો ઉપયોગ કરીને માંગણા નોટીસ જારી કરીને દેવાદાર, જામીનદારો અને ગીરવેદારોને લોન એકાઉન્ટ નંબર હેઠળની રકમ પરત ચુકવવા જણાવ્યું હતું. જેની વિગતો અહીં નીચે કોષ્ટકમાં જણાવેલ છે.

અને જણાવાનું કે ત્યારબાદ મથૂટ હાઉસિંગ ફાયનાન્સ કંપની લીમીટેડે એસાઇનમેન્ટ એગ્રીમેન્ટ તારીખ ૩૧.૦૩.૨૦૨૩ દ્વારા સિક્યોરીટી રીસીપ્ટના હોલ્ડરોના લાભાર્થે **આર્સિલ–રીટેલ લોન પોર્ટ ફોલિયો–૦૮૬–એ–ટ્રસ્ટ (આર્સિલ) ના ટ્રસ્ટી તરીકે** તેની ક્ષમતા કાર્યરત એસેટ રીકન્સ્ટ્રક્શન કંપની (ઇન્ડિયા) લીમીટેડને દેવાદાર/જામીનદારોની મથૂટ હાઉસિંગ ફાયનાન્સ કંપની લીમીટેડ દ્વારા અપાયેલ સવલતોમાંથી દેવાદારો/જામીનદાર(રો)/ગીરવેદાર(રો) ના બાકી ઋણ અને ચુકવવાપાત્ર અને નીચેની સ્થાવર મિલકતોનાં સંબંધમાં તેના તમામ હકો, ટાઇટલ અને હિત અને લાભો સોંપેલ છે. પરિણામે આ એસાઇમેન્ટને જોતાં, આર્સિલ મથૂટ હાઉસિંગ ફાયનાન્સ કંપની લીમીટેડની જગ્યાએ છે અને આર્સિલ દેવાદાર/જામીનદાર(રો)/ગીરવેદારો એ મેળવેલ નાણાંકિય સવલતો માટે તેના દ્વારા કરાયેલ અને સર્જાયેલ ગેરંટી અને સિક્યોરીટી હિતના એન્ફોર્સમેન્ટ તેમજ નાણાંકિય સવલતો હેઠળના હકો અને ફાયદાઓને ટાંચમા લેવા માટે ને સંબંધિત દેવાદારો/જામીનદાર(રો)/ગીરવેદાર(રો) સામે તમામ અને કોઈપણ કાર્યવાહી શરૂ/ચાલુ કરવા હકદાર ગણાશે.

દેવાદાર/જામીનદાર(રો)/ગીરવેદાર(રો) આ રકમોની પરત ચુક્વણી કરવામાં નિષ્ફળ ગયા હોવાથી ખાસ કરીને દેવાદાર/જામીનદાર(રો)/ ગીરવેદાર(રો) અને જાહેર જનતાને આથી નોટીસ આપવામાં આવે છે કે આર્સિલના નીચે સહી કરનાર અધિકૃત અધિકારીએ જણાવેલ નિયમોના નિયમ ૮ સાથે વંચાતી જણાવેલ એક્ટની કલમ ૧૩નીપેટા કલમ (૪) હેઠળ તે/તેણીને પ્રાપ્ત સત્તાનો ઉપયોગ કરીને અહીં નીચે જણાવેલ સ્થાવર મિલકતનો કબજો **''જ્યાં છે'', જે છે'' અને જેમ છે'' ના ધોરણે** અહીં નીચે જણાવેલ તારીખે લઈ લીધો છે.

ક્રમ નં.	દેવાદાર અને જામીનદારોના નામ	માંગણા નોટીસ	મિલકતની વિગત	કબજાની તારીખ
1.	**૧૦૧૦૦૦૦૮૪૦૩ ઝંખના અશોકકુમાર જૈન અને અશોકકુમાર કાળુભાઇ જૈન**	રૂ. ૧૦,૧૩,૭૬૫.૧૬/- (રૂપિયા દસ લાખ તેર હજાર સાતસો પાંસઠ અને સોળ પૈસા પુરા) ૩૧–૦૧–૨૦૨૬ મુજબ નોટીસની તારીખ: ૨૧–૦૨–૨૦૨૬	ફ્લેટ નં. ૧૦૩, પહેલો માળ, બિલ્ડીંગ નં. બી, ક્ષેત્રફળ ૪૮૫ ચો. ફુટ બિલ્ટ–અપ એરિયા, મંજુર મેપના પ્લાન મુજબ જમીન, રેવન્યુ સર્વે નં. ૨૪૫, સાઇઝ ૨૬૩૦ ચો.મી., સલદાર જમીન, વડોદરા મહાનગર સેવા સદન લેટર નંબર એલ/૧૩૬ વોર્ડ–૩/૨૦૧૨–૨૦૧૩, બાંધકામ, 'વૈષ્ણવ વિલોવ', ગામ–દાંતેશ્વરની સીમ, પેટા જિલ્લો અને જિલ્લો–વડોદરા (ડિવિઝન–૨) ખાતેની સ્થાવર મિલકતના તમામ ભાગ અને હિસ્સા. **ચતુ:સીમા :** પુર્વ : કોમન પ્લોટ, પશ્ચિમ : ફ્લેટ નં. બી–૧૦૪, ઉત્તર : શ્રીજી સાંઇ ડુપ્લેક્ષ, દક્ષિણ : ફ્લેટ નં. બી–૧૦૨	**સાંકેતિક કબજો ૨૯–૧૦–૨૦૨૬**

ખાસ કરીને દેવાદાર/જામીનદાર(રો)/ગીરવેદાર(રો) અને જાહેર જનતાને આથી સાવધ કરવામાં આવે છે કે ઉપર જણાવેલ સ્થાવર મિલકતનો કાનુની કબજો આર્સિલ પાસે છે અને સરફૈસી એક્ટ, ૨૦૦૨ ની કલમ ૧૩(૧૩) હેઠળ, દેવાદાર/જામીનદાર(રો)/ગીરવેદાર(રો) અથવા કોઇપણ વ્યક્તિ આ નોટીસ મળ્યા પછી આર્સિલની આગોતરી મંજૂરી વગર સ્થાવર મિલકતનું વેચાણ, ભાડે અથવા અન્ય રીતે સોદો/અન્યના નામે તબદીલ કરી શકશે નહીં અને સ્થાવર મિલકતો સાથેના કોઇપણ સોદા આર્સિલની ઉપર જણાવેલ રકમ તેમજ ઉપર જણાવેલ રકમ પર કરારના દરે ચડત વ્યાજ તેમજ આકસ્મિક ખર્ચ, કોસ્ટ, ચાર્જિસ વગેરેના ચાર્જને આધિન રહેશે.

ઉપર જણાવેલ સ્થાવર મિલકતો છોડાવા માટે ઉપલબ્ધ સમયના સંબંધમાં જણાવેલ એક્ટની કલમ ૧૩ ની પેટા કલમ (૮) ની જોગવાઇઓ પ્રત્યે સંબંધિત દેવાદારો/જામીનદારો/ગીરવેદારોનું ધ્યાન દોરવામાં આવે છે.

સહી/– અધિકૃત અધિકારી,
સ્થળ : ગુજરાત **એસેટ રિકન્સ્ટ્રક્શન કંપની (ઇન્ડિયા) લીમીટેડ**
તારીખ : ૨૮–૧૦–૨૦૨૬ **આર્સિલ–રીટેલ લોન પોર્ટ ફોલિયો–૦૮૬–એ–ટ્રસ્ટના ટ્રસ્ટી**

ODIGMA CONSULTANCY SOLUTIONS LIMITED

[**CIN:** L72900GJ2011PLC131548]
Registered Office: 28th Floor, GIFT Two Building, Block No. 56, Road -5C, Zone-5, GIFT CITY, Gandhinagar - 382050
Email: ir@odigma.ooo, **Tel:** +91 79 6777 2200, **Website:** www.odigma.ooo

EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON SEPTEMBER 30, 2026

(Rupees in lakhs, except per share data and if otherwise stated)

Particulars	Standalone		
	Quarter ended on 30-09-2026 (Unaudited)	Six Months ended on 30-09-2026 (Unaudited)	Quarter ended on 30-09-2025 (Unaudited)
Total income	1,146.01	2,410.05	1,290.78
Net Profit / (Loss) for the period before Tax	17.57	37.16	16.13
Net Profit / (Loss) for the period after tax of continuing operations	13.15	28.03	12.06
Net Profit / (Loss) for the period after tax of discontinued operations	-	-	-
Total Comprehensive Income for the period (comprising Profit / (Loss) for the period after tax and other comprehensive income after tax)	13.15	28.03	12.06
Paid-up equity share capital (Face Value of the share Re 1/- Each)	312.58	312.58	312.58
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-
Earnings Per Share (Face value of Re. 1/- each) (not annualised)			
Basic:	0.04	0.09	0.04
Diluted:	0.04	0.09	0.04

Note:
1) The above financial results are reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on October 27, 2026.
2) The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of financial results are available on the Stock Exchanges websites at www.bseindia.com and www.nseindia.com and on the Company website at www.odigma.ooo. The same can be accessed by scanning the QR Code provided below:

For Odigma Consultancy Solutions Limited
Sd/-
Vishal Mehta
Chairman
DIN: 03093563

Date: October 27, 2026
Place: Gandhinagar

इंजीनियर्स इंडिया लिमिटेड ENGINEERS INDIA LIMITED

(भारत सरकार का उपक्रम) एक नवरत्न कंपनी
(A Govt. of India Undertaking) A Navratna Company

पंजीकृत कार्यालयः इंजीनियर्स इंडिया भवन, 1, भीकाजी कामा प्लेस, नई दिल्ली–110 066, भारत
Regd. Office: Engineers India Bhavan, 1, Bhikaiji Cama Place, New Delhi-110 066, India
ई-मेल/e-mail: company.secretary@eil.co.in, दूरभाष/Phone: 011-26763451
वेबसाइट/Website: www.engineersindia.com, सीआईएन/CIN: L74899DL1965GOI004352
कंपनी सचिवालय/COMPANY SECRETARIAT

Notice to Shareholders – 1st Interim Dividend 2026-27 & Fixation of Record Date

The Board of Directors in their meeting to be held on Friday, the 30th October, 2026 will consider the 1st Interim Dividend for FY 2026-27. The 1st Interim dividend, if declared, in the said meeting, shall be paid to the equity shareholders whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares as on Thursday, 5th November, 2026, which is the Record Date fixed for the purpose. The 1st interim dividend shall be paid to all eligible shareholders through RBI approved electronic modes only.

Pursuant to the Income Tax Act, 2025, the Company would be required to withhold taxes at the prescribed rates on the dividend paid to its shareholders. For details of applicable taxes, list of documents required to be submitted by each category of shareholders and related tax provisions, shareholders are requested to visit our website, www.engineersindia.com.

Any eligible shareholder, who wishes to avail the benefit of non-deduction of tax at source, is requested to ensure that the necessary documents as prescribed above should reach on or before Thursday, 5th November, 2026 to company's Registrar & Transfer Agent, i.e. M/s Alankit Assignments Limited, 205-208, Anarkali Complex, Jhandewalan Extn., New Delhi or by e-mail to rta@alankit.com.

This intimation is also available on the website of the Company at www.engineersindia.com and on the website of the Stock Exchanges where the shares of the Company are listed at www.bseindia.com and www.nseindia.com.

For further clarifications or assistance, you may write to us at:

Mr. Virender Sharma Manager **Unit: Engineers India Limited** M/s. Alankit Assignments Limited 205-208, Anarkali Complex, Jhandewalan Extension, New Delhi-110055 **E-mail ID:** virenders@alankit.com **Tel.:** 011-42541234	**Mr. S.K. Padhi** Company Secretary **Engineers India Limited** El Bhawan, 1, Bhikaiji Cama Place New Delhi-110066 **E-mail ID:** company.secretary@eil.co.in **Tel.:** 011-26763451

For **Engineers India Limited**
Sd/-
S.K. Padhi
Company Secretary

Place: New Delhi
Date: 27.10.2026

Appeal to Members

We solicit the members to update their KYC details like e-mail ids/bank mandate/mobile no. with Registrar and Share Transfer Agent of the Company or to the concerned DP for receiving the Annual Report/Dividend (if any) and other correspondences from the Company through Online modes.

SKIPPER Limited

SKIPPER LIMITED

CIN: L40104WB1981PLC033408
Registered Office : 3A, Loudon Street, 1st Floor, Kolkata - 700017 West Bengal, India
Corporate Office : Tirumala 22, East Topsia Road, 11th Floor, Kolkata - 700046 West Bengal, India
Phone: 033- 22895731, Fax: 033-22895733
Email: investor.relations@skipperlimited.com
Website: www.skipperlimited.com

Notice is hereby given that pursuant to Section 108 and 110 of the Companies Act, 2013 ("the Act") and other applicable provisions, if any, of the Act read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 (including any statutory modification or re-enactment thereof for the time being in force), read with the General Circular No. 3/2022 dated May 5, 2022, General Circular No. 11/2022 dated December 28, 2022 General Circular No. 09/2023 dated September 25, 2023 and General Circular No. 09/2024 dated September 19, 2024 and General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs, Government of India ("MCA Circular"), Secretarial Standard on General Meetings and Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations"), **Skipper Limited** ('the Company') has sent an e-mail on Tuesday, 27th October, 2026 to the Members who have registered their e-mail address with the Depositories (NSDL/CDSL) or with the Registrar and Share Transfer Agent of the Company as on the cut-off date i.e. **Friday, 23rd October, 2026** along with Notice of Postal Ballot together with the Explanatory Statement to transact the business as set out in the Postal Ballot notice dated 12th October, 2026.

The Postal Ballot Notice has been sent to shareholders only through email as per the names received from the Register of Members/List of Beneficial Owners as received from National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as on cut-off date i.e., **Friday, 23rd October, 2026.** A person who is not a Member on the Cut-off date should treat the Notice for information purposes only.

The Notice is available on the website of the Company viz., www.skipperlimited.com and on the website of the stock exchanges where equity shares of the Company are listed viz., www.bseindia.com and www.nseindia.com. The Notice is also available on the e-Voting website of NSDL viz., www.evoting.nsdl.com.

The Company has appointed Mr. Raj Kumar Banthia, (Membership no- A17190/CP-18428), partner of M/s. MKB & Associates, Practicing Company Secretaries, Kolkata as Scrutinizer for conducting the Postal Ballot in a fair and transparent manner and he has communicated his willingness to be appointed as Scrutinizer.

The Company has provided e-voting facility to its members and has engaged National Securities Depository Limited ("NSDL"), an agency authorised by the Ministry of Corporate Affairs ("MCA") for providing e-voting platform. The procedure for e-voting is explained under the Notes provided with this Postal Ballot Notice.

The e-Voting facility would be available during the following period :

Commencement of e-Voting	**9:00 A.M of 29th October, 2026**
End of e-Voting	**5:00 P.M of 27th November, 2026**

Members are requested to record their assent or dissent through the remote e-Voting process not later than 5:00 p.m. (IST) on 27th November, 2026. Remote e-Voting will be blocked by NSDL immediately thereafter and will not be allowed beyond the said date and time. During this period, members of the Company holding shares either in physical or electronic form, as on the cut-off date, i.e. **Friday, 23rd October, 2026,** shall cast their vote electronically. The voting rights shall also be reckoned on the paid-up value of shares registered in the name(s) of the Member(s) as on the cut-off date. Once the vote on a resolution is cast by a Member, the Member shall not be allowed to change it subsequently.

In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-Voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 022 - 4886 7000 or send a request at evoting@nsdl.com.

The Scrutinizer will submit their report to the Company after the completion of scrutiny of E-Vcting and the result of Postal Ballot will be announced not later than two working days from the date of conclusion of Postal Ballot process, at the Registered Office of the Company and also by placing the same on the Company's website: www.skipperlimited.com. The results will simultaneously be communicated to the BSE and NSE. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 022 - 4886 7000 or send a request at evoting@nsdl.com

For **Skipper Limited**
Anu Singh
Sd/-
Company Secretary & Compliance Officer

Place : Kolkata
Dated : 27th October, 2026

CONCORD BIOTECH LIMITED

CONCORD BIOTECH *Biotech for Mankind...*

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 **(Rs. In lakhs except per share data)**

Sr. No	Particulars	Standalone						Consolidated					
		Quarter ended 30/09/2026 Unaudited	Quarter ended 30/06/2026 Unaudited	Quarter ended 30/09/2025 Unaudited	Six Month ended 30/09/2026 Unaudited	Six Month ended 30/09/2025 Unaudited	Year ended 31/03/2026 Audited	Quarter ended 30/09/2026 Unaudited	Quarter ended 30/06/2026 Unaudited	Quarter ended 30/09/2025 Unaudited	Six Month ended 30/09/2026 Unaudited	Six Month ended 30/09/2025 Unaudited	Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	--	--	-	200,929.01	-	--	-	--	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated						Standalone					
		Quarter ended			Six months ended		Year ended	Quarter ended			Six months ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

CONCORD BIOTECH
Biotech for Mankind...

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026 Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items#)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

adani ACC

adani Cement

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026	Preceding 3 months ended 30/06/2026	Corresponding 3 months ended 30/09/2025	Year to date figures for current period from 01/04/2026 to 30/09/2026	Year to date figures for preceding period from 01/04/2025 to 30/09/2025	For the year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026	Preceding 3 months ended 30/06/2026	Corresponding 3 months ended 30/09/2025	Year to date figures for current period from 01/04/2026 to 30/09/2026	Year to date figures for preceding period from 01/04/2025 to 30/09/2025	For the year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026.**

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

CONCORD BIOTECH
Biotech for Mankind...

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Scan QR Code for Financial Results

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:

The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652
Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

CONCORD BIOTECH
Biotech for Mankind...

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Team India Guaranty

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652
Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026.**

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

CONCORD BIOTECH
Biotech for Mankind...

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr. No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.76	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

CONCORD BIOTECH
Biotech for Mankind...

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Team India Guaranty

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652
Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026 Name of the Holder: Bharat Shyam Bhatia

MANBA FINANCE

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items#)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

adani ACC

ACC LIMITED

adani Cement

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. **Tel. No.:** +91 022-40660 660.
Email: distribution@bdrpharma.com, **Web:** www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

CONCORD BIOTECH
Biotech for Mankind...

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr. No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Team India GUARANTY

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:

The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

Chandigarh

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

CONCORD BIOTECH
Biotech for Mankind...

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Team India Guaranty

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652
Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.76	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

CONCORD BIOTECH
Biotech for Mankind...

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026

Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items*)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items*)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026 Unaudited	Preceding 3 months ended 30/06/2026 Unaudited	Corresponding 3 months ended 30/09/2025 Unaudited	Year to date figures for current period from 01/04/2026 to 30/09/2026 Unaudited	Year to date figures for preceding period from 01/04/2025 to 30/09/2025 Unaudited	For the year ended 31/03/2026 Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40560 560
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers**.

CONCORD BIOTECH LIMITED

CONCORD BIOTECH
Biotech for Mankind...

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr. No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Team India GUARANTY

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:
The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

KDDL LIMITED

(CIN : L33302HP1981PLC008123)
Regd. Office: Plot No. 3, Sector – III, Parwanoo, Distt. Solan (H.P.) - 173220
Tel.: +91 172 2548223 / 24 Fax : +91 172 2548302
Website: www.kddl.com Email id: investor.complaints@kddl.com

NOTICE is hereby given that following share certificates issued by the Company are stated to be lost/ misplaced and the claimant thereof has applied to the Company for the issue of duplicate share certificates as per following details:

Folio No.	Name of the Shareholder	Share Certificate Numbers	Distinctive Numbers	No. of Shares
D000437	DARIYA KUNWARI	1425 - 1425 5670 - 5670 64153 - 64156	273551 - 273600 485801 - 485850 2949634 - 2949833	50 50 200

Any person(s) who has/have any claim(s) in respect of the said share certificates should lodge such claims with all supporting documents at the registered office given herein above within 7 days of the publication of this notice. If no valid and legitimate claim is received, the Company will proceed to issue letter of confirmation in lieu of duplicate share certificate(s) to the person listed above and no further claim would be entertained from any other person(s).

For KDDL Limited
Sd/-
Brahm Prakash Kumar
Company Secretary

Place: Chandigarh
Date: 27-10-2026

NOTICE OF LOSS OF SHARE CERTIFICATE

Notice is hereby given that the following equity share certificate(s) of **GlaxoSmithKline Pharmaceuticals Limited (CIN: L24239MH1924PLC001151)** is reported to be lost or misplaced and the holder/claimant thereof have applied for issuance of duplicate shares certificate(s) in lieu thereof.

Sr. No.	Name of the shareholders	Name of the company and Folio No.	Certificate No(s).	Distinctive Nos. From	Distinctive Nos. To	No. of Equity Shares	Face Value
1	Shyam Pahlajrai Bhatia (Deceased), Bharat Shyam Bhatia (Surviving) & Kamla Balram Bhatia (Deceased)	GlaxoSmithKline Pharmaceuticals Limited (0253747)	1104350	16452120	16452144	25	10
2			284675	16452070	16452119	50	
3			284943	16462420	16462469	50	
4			284944	16462470	16462519	50	
5			1284939	171047696	171048123	428	
6			1104351	27361278	27361291	14	
7			1104350	27361270	27361277	8	
8			1104350	27357911	27357927	17	
9			1104351	30896198	30896233	36	
10			1104352	30896234	30896239	6	
11			597339	30896148	30896197	50	
12			598556	30916195	30916244	50	
13			598557	30916245	30916294	50	
14			1104352	30916295	30916316	22	

Public is hereby cautioned against dealing with the aforesaid share certificates.

Date: 28.10.2026 Name of the Holder: Bharat Shyam Bhatia

Manba Finance Limited

Corporate Identity Number (CIN) : L65923MH1996PLC099938
Registered Office: 324, Runwal Heights, L.B.S Marg, Opp. Nirmal Lifestyle, Mulund (West), Mumbai- 400080
Tel no: +91 22 62346666, Email: investorrelation@manbafinance.com, Website: www.manbafinance.com

Extract of Unaudited financial results for the quarter and half ended September 30, 2026 (Reg 47 and 52(8), read with Reg 33 and 52(4), of the SEBI (LODR) Regulations, 2015)

(in lakhs)

Sr. No.	Particulars	Quarter Ended 30th September, 2026 (Unaudited)	Quarter Ended 30th June, 2026 (Unaudited)	Quarter Ended 30th September, 2025 (Unaudited)	Half Period ended 30th September, 2026 (Unaudited)	Half Period ended 30th September, 2025 (Unaudited)	Year ended 31st March 2026 (Audited)
1	Total Income from Operations	9774.36	9260.82	7776.88	19035.18	14477.25	32821.72
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
3	Net Profit/ (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items#)	2171.71	1610.53	1523.91	3782.25	2742.05	6149.95
4	Net Profit/ (Loss) for the period after Tax, (after Exceptional and/or Extraordinary items#)	1373.41	1326.28	1139.81	2699.69	2114.89	4535.64
5	Total Comprehensive income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after Tax)	5.33	6.44	-16.27	11.78	4.02	52.89
6	Paid up Equity Share Capital	5023.94	5023.94	5023.94	5023.94	5023.94	5023.94
7	Reserves (excluding Revaluation Reserves)	23024.08	21896.54	18470.98	23024.08	18470.98	20563.81
8	Securities Premium Account	15388.3	15388.3	15388.3	15388.3	15388.3	15388.3
9	Net Worth	43436.32	42308.78	38883.22	43436.32	38883.22	40976.05
10	Paid Up Debt Capital/ Outstanding Debt	49059.73	45049.74	48206.33	49059.73	48206.33	48287.93
11	Outsourcing Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
12	Debt Equity Ratio	3.61	3.43	3.76	3.61	3.76	3.78
13	*Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)						
	1. Basic	2.73	2.64	2.27	5.37	4.21	9.03
	2. Diluted	2.73	2.64	2.27	5.37	4.21	9.03
14	Capital Redemption Reserves	NA	NA	NA	NA	NA	NA
15	Debenture Redemption Reserves	NA	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

a) The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of Manba Finance Limited ("the Company") at their respective meetings held on October 27, 2026. There are no qualifications in the limited reveiw report issued for the quarter and half year ended 30 September 2026.

b) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 and 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and on the website of company i.e. www.manbafinance.com

c) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE & NSE) and can be accessed on www.bseindia.com and www.nseindia.com

d) The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable

Place: Mumbai
Date: 27-10-2026

For Manba Finance Limited
SD/-
Manish K. Shah
Managing Director
DIN: 00979854

CONCEPT

ACC LIMITED

CIN: L26940GJ1936PLC149771
Registered Office : Adani Corporate House, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad, Gujarat 382421
Tel. No.: +91 79 2656 5555 - Website: www.acclimited.com - E-mail: acc-investorsupport@adani.com

Extract of Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2026

(₹ in Crore)

Particulars	3 months ended 30/09/2026	Preceding 3 months ended 30/06/2026	Corresponding 3 months ended 30/09/2025	Year to date figures for current period from 01/04/2026 to 30/09/2026	Year to date figures for preceding period from 01/04/2025 to 30/09/2025	For the year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Total Revenue from Operations (Including Government grants)	5,689	5,808	6,005	11,497	12,333	25,962
2. Net Profit for the period (before exceptional item, share of profit of associates and joint ventures and tax)	194	222	762	416	1,323	2,122
3. Net Profit for the period before tax (after exceptional item and share of profit of associates and joint ventures)	124	200	763	324	1,326	2,157
4. Net Profit for the period after tax (after exceptional item and share of profit of associates and joint ventures)	93	147	1,119	240	1,495	2,137
5. Total Comprehensive Income for the period	118	149	1,151	267	1,519	2,136
6. Paid-up Equity Share Capital	188	188	188	188	188	188
7. Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						20,362
8. Earnings per share of ₹10 each (not annualised):						
(a) Basic ₹	4.95	7.83	59.60	12.78	79.59	113.80
(b) Diluted ₹	4.94	7.81	59.45	12.75	79.38	113.51

Key numbers of standalone unaudited results of the Company are as under :-

(₹ in Crore)

Particulars	3 months ended 30/09/2026	Preceding 3 months ended 30/06/2026	Corresponding 3 months ended 30/09/2025	Year to date figures for current period from 01/04/2026 to 30/09/2026	Year to date figures for preceding period from 01/04/2025 to 30/09/2025	For the year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Total Revenue from Operations (Including Government grants)	5,635	5,766	5,926	11,401	12,233	25,766
2. Net Profit for the period before tax (after exceptional item)	129	198	757	327	1,330	2,307
3. Net Profit for the period after tax (after exceptional item)	101	148	1,112	249	1,497	2,287
4. Total Comprehensive Income for the period	126	150	1,143	276	1,522	2,286

Note :

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the Company's website, www.ambujacement.com and on the stock exchanges websites www.bseindia.com and www.nseindia.com

For and on behalf of the Board of Directors

Vinod Bahety
Wholetime Director & Chief Executive Officer
DIN: 09192400

Place: Ahmedabad
Date: October 27 , 2026

BDR Pharmaceuticals International Private Limited

CIN No.: U24230MH2002PTC137329
Corporate Office: Tower B, 16th Floor, Unit No.: 1601-02, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91 022-40660 660.
Email: distribution@bdrpharma.com, Web: www.bdrpharma.com

PUBLIC NOTICE

In line with NPPA Order **S. O. 5690 (E) dated 17 October 2026**, BDR Pharmaceuticals International Private Limited has revised the Maximum Retail Price (MRPs) of its applicable anti-cancer medicines, effective **9 November 2026**.

The revised MRP for the applicable products of BDR Pharmaceuticals International Private Limited may be accessed by scanning the QR code.

All channel partners of BDR Pharmaceuticals International Private Limited including distributors, stockists retailers, hospitals, health centres etc. are hereby advised and required to **ensure that the benefit of the revised MRP is available to all patients and consumers.**

CONCORD BIOTECH LIMITED

CONCORD BIOTECH
Biotech for Mankind...

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || **Phone No.** : +91-79-68138700
Fax : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440 || **Email Id** : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || **Phone No.** : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED SEPTEMBER 30, 2026 (Rs. In lakhs except per share data)

Sr. No	Particulars	Standalone Quarter ended 30/09/2026 Unaudited	Standalone Quarter ended 30/06/2026 Unaudited	Standalone Quarter ended 30/09/2025 Unaudited	Standalone Six Month ended 30/09/2026 Unaudited	Standalone Six Month ended 30/09/2025 Unaudited	Standalone Year ended 31/03/2026 Audited	Consolidated Quarter ended 30/09/2026 Unaudited	Consolidated Quarter ended 30/06/2026 Unaudited	Consolidated Quarter ended 30/09/2025 Unaudited	Consolidated Six Month ended 30/09/2026 Unaudited	Consolidated Six Month ended 30/09/2025 Unaudited	Consolidated Year ended 31/03/2026 Audited
1	Total Income from Operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	105,507.10	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	105,489.07
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	200,929.01	-	-	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)												
	1) Basic	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78
	2) Diluted	7.24	5.85	6.01	13.09	10.08	25.17	6.65	5.52	6.03	12.17	10.24	24.78

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly/Yearly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly/Yearly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.
(c) The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 27, 2026

Scan QR Code for Financial Results

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : October 27, 2026

Team India Guaranty

TEAM INDIA GUARANTY LIMITED

Regd. Off: A 201, Level 2 Marathon NextGen Innova Ganpat Rao Kadam Marg Lower Parel (W) Mumbai- 400013
Tel: 022 48818487, Email: info@teamindiaguarantylimited.com
CIN: L65920MH1989PLC054398, Website: www.teamindiaguarantylimited.com

POSTAL BALLOT NOTICE

Notice is hereby given that the resolutions set out below are proposed for approval by the Members of **Team India Guaranty Limited** ("the Company") by means of Postal Ballot, only through remote e-voting process ("e-voting") being provided by the Company to all its Members to cast their votes electronically, pursuant to the provisions of Section 108 and Section 110 of the Companies Act, 2013 ("Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("Rules") and other applicable provisions of the Act and the Rules, Secretarial Standard on General Meetings ("SS-2") issued by the Institute of Company Secretaries of India, General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020 read with other relevant circulars, including General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 08, 2021, General Circular No. 11/2022 dated December 28, 2022, and the latest one being General Circular no. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs ("MCA Circulars"), read with SEBI Master Circular Nos. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 07, 2023 (hereinafter collectively referred to as "SEBI Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force and as amended from time to time).

Members may also note that the copy of the Notice of Postal Ballot will also be available on the Company's website i.e. https://teamindiaguarantylimited.com, and on website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of the Central Depository Services (India) Limited (CDSL) at www.evotingindia.com.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Secretarial Standard on General Meeting (SS-2), Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and MCA Circulars and SEBI Circulars, the Company is pleased to provide to its Members the facility to exercise their voting rights through remote e-voting in respect of the resolution set out in the Postal Ballot Notice. For this purpose, the Company has engaged CDSL to facilitate voting through remote e-Voting.

M/s. Aabid & Co., Company Secretaries have been appointed as the Scrutinizer for conducting the Postal Ballot process through e-voting in a fair and transparent manner.

All the Members are hereby informed that:

The Company has completed the dispatch of Postal Ballot Notice on 27th October 2026 to those shareholders whose email id are registered with the Company/Depository Participants/ Registrar & Share Transfer Agent ("RTA") of the Company i.e., MUFG Intime India Private Limited.

1. The Remote e-Voting period commences on Thursday, 29th October 2026 (9:00 a.m.) and ends on Sunday, 29th November 2026 (5:00 p.m.). The Remote e-Voting module shall be disabled by CDSL thereafter.
2. The Members of the Company holding shares either in physical form or dematerialized form as on cut-off date i.e., 23rd October 2026, only shall be entitled to avail the facility of remote e-Voting.
3. The voting rights of the Members shall be in proportion to their shareholding in the Company as on 23rd October 2026 (cut-off date). Any person, who acquire shares and became the Member of the Company after dispatch of the Notice but before the cut-off date (i.e., 23rd October 2026), may obtain Sequence Number by sending a request to the Company's RTA, M/s. MUFG Intime India Private Limited at an email id: investor.helpdesk@in.mpms.mufg.com.
4. In case you have any queries or issues regarding e-Voting, you may refer the Frequently Asked Questions ("FAQ") and e-Voting manual available at www.evotingindia.com, under the help section or write an email to helpdesk.evoting@cdslindia.com
5. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, AVP, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911.
6. Please keep your most updated email id registered with the Company/Depository Participant to receive the timely communication.
7. The results of the Remote e-voting shall be declared not later than two working days from the closing of Remote E-Voting. The Results declared along with the Scrutinizer's Report, shall be placed on the Company's website viz., https://teamindiaguarantylimited.com, immediately after declaration, and will be communicated to BSE Limited and National Stock Exchange of India Limited.

For any query/ clarification or assistance required with respect to Postal Ballot, the Members may write to info@teamindiaguarantylimited.com.

Place: Mumbai
Date: 28th October 2026

For Team India Guaranty Limited
Sd/-
Aarti Pandey
Company Secretary & Compliance Officer

OneSource Specialty Pharma Limited

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai-400703
Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com

Unaudited Financial Results for the Quarter and six months ended September 30, 2026

(Rs. in Million)

Sl. No.	Particulars	Consolidated Quarter ended September 30, 2026	Consolidated Quarter ended June 30, 2026	Consolidated Quarter ended September 30, 2025	Consolidated Six months ended September 30, 2026	Consolidated Six months ended September 30, 2025	Consolidated Year ended March 31, 2026	Standalone Quarter ended September 30, 2026	Standalone Quarter ended June 30, 2026	Standalone Quarter ended September 30, 2025	Standalone Six months ended September 30, 2026	Standalone Six months ended September 30, 2025	Standalone Year ended March 31, 2026
1	Revenue from Operations	5,162.42	4,490.23	3,757.63	9,652.65	7,030.33	14,215.90	5,144.96	4,464.71	3,751.87	9,609.67	6,961.99	14,053.81
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	546.32	245.94	57.41	792.26	42.12	(820.34)	861.92	512.25	371.01	1,374.17	619.16	266.30
3	Net Profit/ (Loss) for the period after tax (before Exceptional and/ or Extraordinary items)	592.51	292.97	104.85	885.48	131.69	(638.76)	861.92	512.25	371.01	1,374.17	619.16	266.30
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	574.84	249.97	104.85	824.81	102.99	(738.03)	861.92	512.25	371.01	1,374.17	619.16	212.10
5	Earnings Per Share (of Re.1/- each)												
	1. Basic:	5.01	2.18	0.92	7.19	0.90	(6.44)	7.52	4.47	3.24	11.98	5.41	1.85
	2. Diluted:	5.01	2.18	0.91	7.19	0.90	(6.44)	7.51	4.47	3.24	11.98	5.40	1.85

Note:

The above is an extract of the detailed format of the Statement of Consolidated and Standalone Financials Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The full format of the Consolidated and Standalone Financials Results for the quarter and six months ended September 30, 2026 are available on the website of Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.onesourcecdmo.com. The same can be accessed by scanning the QR code provided below.

By order of the Board
Neeraj Sharma
Managing Director
DIN : 09402652

Place: Bengaluru
Date : October 27, 2026

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.